KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to -$65.3 million.

  • Travere Therapeutics' Cash from Financing Activities fell 14214130.43% to -$65.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.0 million, marking a year-over-year increase of 1141209.91%. This contributed to the annual value of $139.4 million for FY2024, which is 3666.49% down from last year.
  • Per Travere Therapeutics' latest filing, its Cash from Financing Activities stood at -$65.3 million for Q3 2025, which was down 14214130.43% from $1.5 million recorded in Q2 2025.
  • Travere Therapeutics' 5-year Cash from Financing Activities high stood at $217.6 million for Q1 2023, and its period low was -$65.3 million during Q3 2025.
  • Moreover, its 5-year median value for Cash from Financing Activities was $1.5 million (2025), whereas its average is $34.6 million.
  • In the last 5 years, Travere Therapeutics' Cash from Financing Activities skyrocketed by 3622349.87% in 2024 and then plummeted by 14214130.43% in 2025.
  • Quarter analysis of 5 years shows Travere Therapeutics' Cash from Financing Activities stood at $39.3 million in 2021, then tumbled by 97.06% to $1.2 million in 2022, then crashed by 66.84% to $383000.0 in 2023, then surged by 36223.5% to $139.1 million in 2024, then tumbled by 146.97% to -$65.3 million in 2025.
  • Its Cash from Financing Activities stands at -$65.3 million for Q3 2025, versus $1.5 million for Q2 2025 and $3.7 million for Q1 2025.